{
    "id": "27d0aa66-f3ad-470a-b753-09dac06e3cae",
    "result_metadata": {
        "score": 1
    },
    "copyright": "",
    "geoOrigin": "",
    "sourceType": "",
    "source": "",
    "corpus_document_id": "13448854078086690027",
    "description": "1:04 AM: Novavax Awarded Department of Defense Contract for COVID-19 Vaccine",
    "serviceName": "AMC User - Energy",
    "locationCode": [],
    "sourceClass": "",
    "subjectCode": [
        {
            "parent": null,
            "relevance_score": "9",
            "description": "Business and Commerce",
            "code": "IS/biz#9#50#99",
            "level": 0
        },
        {
            "parent": "IS/biz",
            "relevance_score": "9",
            "description": "Business Impact",
            "code": "IS/biz.impact#9#50#99",
            "level": 1
        },
        {
            "parent": "IS/impact.ops",
            "relevance_score": "9",
            "description": "Sales and Contract Wins",
            "code": "IS/biz.saleswin#9#99#87",
            "level": 2
        },
        {
            "parent": null,
            "relevance_score": "9",
            "description": "Health and Wellness",
            "code": "IS/haw#9#50#99",
            "level": 0
        }
    ],
    "text": "rintail a friendore announcementsriday 05 une, 2020ovavax, nc.ovavax warded\nepartment of efense ontract for -19 accine$60 million funding for\nmanufacturing of -o237310 million doses to be delivered to o in 2020, d., une\n04, 2020 ( ) -- ovavax, nc. (: ), a late-stage biotechnology company\ndeveloping next-generation vaccines for serious infectious diseases, today\nannounced that the company has been awarded a contract by the .. epartment of\nefense (o) for the manufacturing of \u2011o2373, ovavax' -19 vaccine candidate.\n\u2011o2373 consists of a stable, prefusion protein antigen made using its\nproprietary nanoparticle technology and includes ovavax' proprietary atrix\u2011\u2122\nadjuvant.-- through funding provided by the efense ealth rogram, has agreed to\nfund up to $60 million to support ovavax in its production of several\ncomponents of the vaccine that will be manufactured in the .. he agreement\nincludes a 2020 delivery of 10 million doses of \u2011o2373 for o that could be\nused in hase 2/3 clinical trials or under an mergency se uthorization () if\napproved by the .. .\"e are genuinely honored at the opportunity to protect our\nmilitary personnel and their families who have devoted themselves to the needs\nof .. citizens and others worldwide,\" said tanley . rck, resident and hief\nxecutive fficer of ovavax. \"mportantly, this award will allow ovavax to\nsignificantly expand its .. production capacity of -o2373, a critical step in\nour ability to provide vaccine support to the -19 pandemic.\"s part of the\ncontract, ovavax will work with a ..-based biologics contract development\nmanufacturing organization () to manufacture the antigen component of -o2373\nfor at least 10 million doses of vaccine. ovavax will also collaborate with\n..-based s to scale up production and manufacture of the atrix- adjuvant\ncomponent of the vaccine.bout the -he oint rogram xecutive ffice for hemical,\niological, adiological and uclear efense is the oint ervice's lead for\ndevelopment, acquisition, fielding and life-cycle support of chemical,\nbiological, radiological and nuclear defense equipment and medical\ncountermeasures. s an effective acquisition program, we put capable and\nsupportable systems in the hands of the service members and first responders,\nwhen and where it is needed, at an affordable price. ur vision is a resilient\noint orce enabled to fight and win unencumbered by a chemical, biological,\nradiological, or nuclear environment; championed by innovative and state-of-\nthe-art solutions. nabling iotechnologies () is an organization established\nfor the purpose of providing medical solutions, during a crisis, against\nfuture threats.bout -o2373\u2011o2373 is a vaccine candidate engineered from the\ngenetic sequence of \u2011o\u20112, the virus that causes -19 disease. \u2011o2373 was\ncreated using ovavax' recombinant nanoparticle technology to generate antigen\nderived from the coronavirus spike () protein and contains ovavax' patented\nsaponin-based atrix-\u2122 adjuvant to enhance the immune response and stimulate\nhigh levels of neutralizing antibodies. n preclinical trials, \u2011o2373\ndemonstrated indication of antibodies that block binding of spike protein to\nreceptors targeted by the virus, a critical aspect for effective vaccine\nprotection. hase 1 clinical trial of \u2011o2373 initiated in ay 2020, with\npreliminary immunogenicity and safety results expected in uly 2020. he\noalition for pidemic reparedness nnovations () is investing up to $388 million\nof funding to advance clinical development of \u2011o2373.bout atrix-\u2122ovavax'\npatented saponin-based atrix-\u2122 adjuvant has demonstrated a potent and well-\ntolerated effect by stimulating the entry of antigen-presenting cells into the\ninjection site and enhancing antigen presentation in local lymph nodes,\nboosting immune response.bout ovavaxovavax, nc. (asdaq:) is a late-stage\nbiotechnology company that promotes improved health globally through the\ndiscovery, development, and commercialization of innovative vaccines to\nprevent serious infectious diseases. ovavax recently initiated development of\n-o2373, its vaccine candidate against -o-2, the virus that causes -19, with\nhase 1 clinical trial results expected in uly of 2020. anolu\u2122, its\nquadrivalent influenza nanoparticle vaccine, met all primary objectives in its\npivotal hase 3 clinical trial in older adults. oth vaccine candidates\nincorporate ovavax' proprietary saponin-based atrix-\u2122 adjuvant in order to\nenhance the immune response and stimulate high levels of neutralizing\nantibodies. ovavax is a leading innovator of recombinant vaccines; its\nproprietary recombinant technology platform combines the power and speed of\ngenetic engineering to efficiently produce highly immunogenic nanoparticles in\norder to address urgent global health needs.or more information,\nvisitwww.novavax.comwitterinkednorward-ooking tatementstatements herein\nrelating to the future of ovavax and the ongoing development of its vaccine\nand adjuvant products, including statements regarding the manufacturing of\nvaccine antigen dose amounts and timing, are forward-looking statements.\novavax cautions that these forward-looking statements are subject to numerous\nrisks and uncertainties, which could cause actual results to differ materially\nfrom those expressed or implied by such statements. hese risks and\nuncertainties include those identified under the heading \"isk actors\" in the\novavax nnual eport on orm 10- for the year ended ecember 31, 2019, as filed\nwith the ecurities and xchange ommission () and updated by any uarterly eport\non orm 10-, particularly the risks inherent to developing novel vaccines. e\ncaution investors not to place considerable reliance on the forward-looking\nstatements contained in this press release. ou are encouraged to read our\nfilings with the , available atsec.govontacts:nvestors[email\nprotected]estwickeedia",
    "industryCode": [
        {
            "parent": "II/hcare.biopharm",
            "relevance_score": "7",
            "description": "Vaccines",
            "code": "II/biotech.vaccines#7#78#50",
            "level": 2
        },
        {
            "parent": "II/hcare.pharma",
            "relevance_score": "7",
            "description": "Biopharmaceuticals",
            "code": "II/hcare.biopharm#7#70#78",
            "level": 1
        },
        {
            "parent": null,
            "relevance_score": "7",
            "description": "Biotechnology",
            "code": "II/hcare.biotech#7#70#78",
            "level": 0
        },
        {
            "parent": null,
            "relevance_score": "7",
            "description": "Pharmaceuticals",
            "code": "II/hcare.pharma#7#50#78",
            "level": 0
        }
    ],
    "naviga_enrichment": {
        "org": [],
        "location": [],
        "person": [],
        "companies": []
    },
    "geoOrigin_code": "",
    "language": "en",
    "filename": "202006042334AMSPIDERAMC_USRE_INVES001_EBB61F073F751D6270D92E69021CDBFE_1.XML",
    "providerName": "Acquire Media Spider",
    "enriched_text": {
        "entities": [
            {
                "count": 11,
                "sentiment": {
                    "score": -0.388144,
                    "label": "negative"
                },
                "text": "ovavax",
                "relevance": 0.872339,
                "type": "Company"
            },
            {
                "count": 2,
                "sentiment": {
                    "score": 0,
                    "label": "neutral"
                },
                "text": "nc",
                "relevance": 0.39068,
                "type": "Location",
                "disambiguation": {
                    "subtype": [
                        "StateOrCounty"
                    ]
                }
            },
            {
                "count": 1,
                "sentiment": {
                    "score": 0,
                    "label": "neutral"
                },
                "text": "uclear efense",
                "relevance": 0.346851,
                "type": "GeographicFeature"
            },
            {
                "count": 1,
                "sentiment": {
                    "score": 0,
                    "label": "neutral"
                },
                "text": "ovavax",
                "relevance": 0.345561,
                "type": "Person"
            },
            {
                "count": 1,
                "sentiment": {
                    "score": -0.298341,
                    "label": "negative"
                },
                "text": "oint orce",
                "relevance": 0.321404,
                "type": "Person"
            },
            {
                "count": 1,
                "sentiment": {
                    "score": 0,
                    "label": "neutral"
                },
                "text": "xecutive fficer",
                "relevance": 0.31871,
                "type": "Person"
            },
            {
                "count": 1,
                "sentiment": {
                    "score": 0,
                    "label": "neutral"
                },
                "text": "atrix",
                "relevance": 0.308322,
                "type": "Company"
            },
            {
                "count": 1,
                "sentiment": {
                    "score": 0,
                    "label": "neutral"
                },
                "text": "hief",
                "relevance": 0.30458,
                "type": "Location",
                "disambiguation": {
                    "subtype": [
                        "City"
                    ]
                }
            },
            {
                "count": 1,
                "sentiment": {
                    "score": 0,
                    "label": "neutral"
                },
                "text": "mportantly",
                "relevance": 0.298559,
                "type": "Person"
            },
            {
                "count": 1,
                "sentiment": {
                    "score": 0,
                    "label": "neutral"
                },
                "text": "uly",
                "relevance": 0.293958,
                "type": "Location",
                "disambiguation": {
                    "subtype": [
                        "City"
                    ]
                }
            },
            {
                "count": 1,
                "sentiment": {
                    "score": 0,
                    "label": "neutral"
                },
                "text": "$388 million",
                "relevance": 0.280053,
                "type": "Quantity"
            },
            {
                "count": 1,
                "sentiment": {
                    "score": 0,
                    "label": "neutral"
                },
                "text": "$60 million",
                "relevance": 0.280053,
                "type": "Quantity"
            }
        ],
        "semantic_roles": [
            {
                "subject": {
                    "text": "manufacturing of -o237310 million doses"
                },
                "sentence": " manufacturing of -o237310 million doses to be delivered to o in 2020, d., une",
                "object": {
                    "text": "delivered to o in 2020"
                },
                "action": {
                    "verb": {
                        "text": "be",
                        "tense": "future"
                    },
                    "text": "be",
                    "normalized": "be"
                }
            },
            {
                "subject": {
                    "text": "manufacturing of -o237310 million doses"
                },
                "sentence": " manufacturing of -o237310 million doses to be delivered to o in 2020, d., une",
                "object": {
                    "text": "to o in 2020"
                },
                "action": {
                    "verb": {
                        "text": "deliver",
                        "tense": "past"
                    },
                    "text": "delivered",
                    "normalized": "deliver"
                }
            },
            {
                "subject": {
                    "text": "next-generation vaccines"
                },
                "sentence": " developing next-generation vaccines for serious infectious diseases, today",
                "action": {
                    "verb": {
                        "text": "develop",
                        "tense": "present"
                    },
                    "text": "developing",
                    "normalized": "develop"
                }
            },
            {
                "subject": {
                    "text": "the company"
                },
                "sentence": " announced that the company has been awarded a contract by the .. epartment of",
                "object": {
                    "text": "been awarded a contract"
                },
                "action": {
                    "verb": {
                        "text": "have",
                        "tense": "present"
                    },
                    "text": "has",
                    "normalized": "have"
                }
            },
            {
                "subject": {
                    "text": "the company"
                },
                "sentence": " announced that the company has been awarded a contract by the .. epartment of",
                "object": {
                    "text": "a contract"
                },
                "action": {
                    "verb": {
                        "text": "award",
                        "tense": "past"
                    },
                    "text": "has been awarded",
                    "normalized": "have be award"
                }
            },
            {
                "subject": {
                    "text": "\u2011o2373"
                },
                "sentence": " \u2011o2373 consists of a stable, prefusion protein antigen made using its",
                "object": {
                    "text": "of a stable, prefusion protein antigen made using its"
                },
                "action": {
                    "verb": {
                        "text": "consist",
                        "tense": "present"
                    },
                    "text": "consists",
                    "normalized": "consist"
                }
            },
            {
                "subject": {
                    "text": "a stable, prefusion protein antigen"
                },
                "sentence": " \u2011o2373 consists of a stable, prefusion protein antigen made using its",
                "object": {
                    "text": "its"
                },
                "action": {
                    "verb": {
                        "text": "use",
                        "tense": "present"
                    },
                    "text": "using",
                    "normalized": "use"
                }
            },
            {
                "subject": {
                    "text": "ovavax' proprietary atrix\u2011\u2122"
                },
                "sentence": " proprietary nanoparticle technology and includes ovavax' proprietary atrix\u2011\u2122",
                "object": {
                    "text": "proprietary nanoparticle"
                },
                "action": {
                    "verb": {
                        "text": "include",
                        "tense": "present"
                    },
                    "text": "includes",
                    "normalized": "include"
                }
            },
            {
                "subject": {
                    "text": "by the efense ealth rogram"
                },
                "sentence": " adjuvant.-- through funding provided by the efense ealth rogram, has agreed to",
                "object": {
                    "text": "funding"
                },
                "action": {
                    "verb": {
                        "text": "provide",
                        "tense": "past"
                    },
                    "text": "provided",
                    "normalized": "provide"
                }
            },
            {
                "subject": {
                    "text": "ovavax"
                },
                "sentence": " fund up to $60 million to support ovavax in its production of several",
                "action": {
                    "verb": {
                        "text": "support",
                        "tense": "future"
                    },
                    "text": "to support",
                    "normalized": "to support"
                }
            },
            {
                "subject": {
                    "text": "military personnel and their families"
                },
                "sentence": " military personnel and their families who have devoted themselves to the needs",
                "object": {
                    "text": "devoted themselves to the needs"
                },
                "action": {
                    "verb": {
                        "text": "have",
                        "tense": "present"
                    },
                    "text": "have",
                    "normalized": "have"
                }
            },
            {
                "subject": {
                    "text": "military personnel and their families"
                },
                "sentence": " military personnel and their families who have devoted themselves to the needs",
                "object": {
                    "text": "themselves"
                },
                "action": {
                    "verb": {
                        "text": "devote",
                        "tense": "past"
                    },
                    "text": "have devoted",
                    "normalized": "have devote"
                }
            },
            {
                "subject": {
                    "text": "tanley . rck, resident and hief"
                },
                "sentence": " of .. citizens and others worldwide,\" said tanley . rck, resident and hief",
                "object": {
                    "text": "of .. citizens and others worldwide"
                },
                "action": {
                    "verb": {
                        "text": "say",
                        "tense": "past"
                    },
                    "text": "said",
                    "normalized": "say"
                }
            },
            {
                "subject": {
                    "text": "this award"
                },
                "sentence": " \"mportantly, this award will allow ovavax to",
                "object": {
                    "text": "ovavax to"
                },
                "action": {
                    "verb": {
                        "text": "allow",
                        "tense": "future"
                    },
                    "text": "will allow",
                    "normalized": "will allow"
                }
            },
            {
                "subject": {
                    "text": "vaccine support"
                },
                "sentence": " our ability to provide vaccine support to the -19 pandemic.\"s part of the",
                "object": {
                    "text": "to the -19 pandemic."
                },
                "action": {
                    "verb": {
                        "text": "provide",
                        "tense": "future"
                    },
                    "text": "to provide",
                    "normalized": "to provide"
                }
            },
            {
                "subject": {
                    "text": "manufacturing organization"
                },
                "sentence": " manufacturing organization () to manufacture the antigen component of -o2373",
                "object": {
                    "text": "the antigen component of -o2373"
                },
                "action": {
                    "verb": {
                        "text": "manufacture",
                        "tense": "future"
                    },
                    "text": "to manufacture",
                    "normalized": "to manufacture"
                }
            },
            {
                "subject": {
                    "text": "iological, adiological and uclear efense"
                },
                "sentence": " iological, adiological and uclear efense is the oint ervice's lead for",
                "object": {
                    "text": "the oint ervice's lead"
                },
                "action": {
                    "verb": {
                        "text": "be",
                        "tense": "present"
                    },
                    "text": "is",
                    "normalized": "be"
                }
            },
            {
                "subject": {
                    "text": "we"
                },
                "sentence": " countermeasures. s an effective acquisition program, we put capable and",
                "object": {
                    "text": "capable"
                },
                "action": {
                    "verb": {
                        "text": "put",
                        "tense": "past"
                    },
                    "text": "put",
                    "normalized": "put"
                }
            },
            {
                "subject": {
                    "text": "it"
                },
                "sentence": " when and where it is needed, at an affordable price. ur vision is a resilient",
                "object": {
                    "text": "needed"
                },
                "action": {
                    "verb": {
                        "text": "be",
                        "tense": "present"
                    },
                    "text": "is",
                    "normalized": "be"
                }
            },
            {
                "subject": {
                    "text": "at an affordable price. ur vision"
                },
                "sentence": " when and where it is needed, at an affordable price. ur vision is a resilient",
                "object": {
                    "text": "a resilient"
                },
                "action": {
                    "verb": {
                        "text": "be",
                        "tense": "present"
                    },
                    "text": "is",
                    "normalized": "be"
                }
            },
            {
                "subject": {
                    "text": "oint orce"
                },
                "sentence": " oint orce enabled to fight and win unencumbered by a chemical, biological,",
                "object": {
                    "text": "to fight and win unencumbered by a chemical, biological,"
                },
                "action": {
                    "verb": {
                        "text": "enable",
                        "tense": "past"
                    },
                    "text": "enabled",
                    "normalized": "enable"
                }
            },
            {
                "subject": {
                    "text": "oint"
                },
                "sentence": " oint orce enabled to fight and win unencumbered by a chemical, biological,",
                "object": {
                    "text": "unencumbered by a chemical, biological,"
                },
                "action": {
                    "verb": {
                        "text": "win",
                        "tense": "present"
                    },
                    "text": "win",
                    "normalized": "win"
                }
            },
            {
                "subject": {
                    "text": "the-art solutions."
                },
                "sentence": " the-art solutions. nabling iotechnologies () is an organization established",
                "object": {
                    "text": "iotechnologies"
                },
                "action": {
                    "verb": {
                        "text": "nabling",
                        "tense": "present"
                    },
                    "text": "nabling",
                    "normalized": "nabling"
                }
            },
            {
                "subject": {
                    "text": "the-art solutions. nabling iotechnologies ()"
                },
                "sentence": " the-art solutions. nabling iotechnologies () is an organization established",
                "object": {
                    "text": "an organization established"
                },
                "action": {
                    "verb": {
                        "text": "be",
                        "tense": "present"
                    },
                    "text": "is",
                    "normalized": "be"
                }
            },
            {
                "subject": {
                    "text": "medical solutions"
                },
                "sentence": " for the purpose of providing medical solutions, during a crisis, against",
                "action": {
                    "verb": {
                        "text": "provide",
                        "tense": "future"
                    },
                    "text": "providing",
                    "normalized": "provide"
                }
            },
            {
                "subject": {
                    "text": "future threats.bout -o2373\u2011o2373"
                },
                "sentence": " future threats.bout -o2373\u2011o2373 is a vaccine candidate engineered from the",
                "object": {
                    "text": "a vaccine candidate"
                },
                "action": {
                    "verb": {
                        "text": "be",
                        "tense": "present"
                    },
                    "text": "is",
                    "normalized": "be"
                }
            },
            {
                "subject": {
                    "text": "the virus"
                },
                "sentence": " genetic sequence of \u2011o\u20112, the virus that causes -19 disease.",
                "object": {
                    "text": "-19 disease"
                },
                "action": {
                    "verb": {
                        "text": "cause",
                        "tense": "present"
                    },
                    "text": "causes",
                    "normalized": "cause"
                }
            },
            {
                "subject": {
                    "text": "ovavax' recombinant nanoparticle technology"
                },
                "sentence": " created using ovavax' recombinant nanoparticle technology to generate antigen",
                "object": {
                    "text": "antigen"
                },
                "action": {
                    "verb": {
                        "text": "generate",
                        "tense": "future"
                    },
                    "text": "to generate",
                    "normalized": "to generate"
                }
            },
            {
                "subject": {
                    "text": "the immune response"
                },
                "sentence": " saponin-based atrix-\u2122 adjuvant to enhance the immune response and stimulate",
                "object": {
                    "text": "saponin-based atrix-\u2122 adjuvant"
                },
                "action": {
                    "verb": {
                        "text": "enhance",
                        "tense": "future"
                    },
                    "text": "to enhance",
                    "normalized": "to enhance"
                }
            },
            {
                "subject": {
                    "text": "antibodies"
                },
                "sentence": " demonstrated indication of antibodies that block binding of spike protein to",
                "object": {
                    "text": "binding of spike protein"
                },
                "action": {
                    "verb": {
                        "text": "block",
                        "tense": "present"
                    },
                    "text": "block",
                    "normalized": "block"
                }
            },
            {
                "subject": {
                    "text": "antibodies"
                },
                "sentence": " demonstrated indication of antibodies that block binding of spike protein to",
                "object": {
                    "text": "of spike protein"
                },
                "action": {
                    "verb": {
                        "text": "bind",
                        "tense": "present"
                    },
                    "text": "block binding",
                    "normalized": "block bind"
                }
            },
            {
                "subject": {
                    "text": "protection. hase 1 clinical trial of \u2011o2373"
                },
                "sentence": " protection. hase 1 clinical trial of \u2011o2373 initiated in ay 2020, with",
                "action": {
                    "verb": {
                        "text": "initiate",
                        "tense": "past"
                    },
                    "text": "initiated",
                    "normalized": "initiate"
                }
            },
            {
                "subject": {
                    "text": "oalition for pidemic reparedness nnovations ()"
                },
                "sentence": " oalition for pidemic reparedness nnovations () is investing up to $388 million",
                "object": {
                    "text": "investing up to $388 million"
                },
                "action": {
                    "verb": {
                        "text": "be",
                        "tense": "present"
                    },
                    "text": "is",
                    "normalized": "be"
                }
            },
            {
                "subject": {
                    "text": "oalition for pidemic reparedness nnovations ()"
                },
                "sentence": " oalition for pidemic reparedness nnovations () is investing up to $388 million",
                "object": {
                    "text": "up to $388 million"
                },
                "action": {
                    "verb": {
                        "text": "invest",
                        "tense": "present"
                    },
                    "text": "is investing",
                    "normalized": "be invest"
                }
            },
            {
                "subject": {
                    "text": "patented saponin-based atrix-\u2122 adjuvant"
                },
                "sentence": " patented saponin-based atrix-\u2122 adjuvant has demonstrated a potent and well-",
                "object": {
                    "text": "demonstrated a potent and well-"
                },
                "action": {
                    "verb": {
                        "text": "have",
                        "tense": "present"
                    },
                    "text": "has",
                    "normalized": "have"
                }
            },
            {
                "subject": {
                    "text": "patented saponin-based atrix-\u2122 adjuvant"
                },
                "sentence": " patented saponin-based atrix-\u2122 adjuvant has demonstrated a potent and well-",
                "object": {
                    "text": "a potent"
                },
                "action": {
                    "verb": {
                        "text": "demonstrate",
                        "tense": "past"
                    },
                    "text": "has demonstrated",
                    "normalized": "have demonstrate"
                }
            },
            {
                "subject": {
                    "text": "biotechnology company"
                },
                "sentence": " biotechnology company that promotes improved health globally through the",
                "object": {
                    "text": "improved health"
                },
                "action": {
                    "verb": {
                        "text": "promote",
                        "tense": "present"
                    },
                    "text": "promotes",
                    "normalized": "promote"
                }
            },
            {
                "subject": {
                    "text": "development"
                },
                "sentence": " prevent serious infectious diseases. ovavax recently initiated development of",
                "object": {
                    "text": "serious infectious diseases. ovavax"
                },
                "action": {
                    "verb": {
                        "text": "initiate",
                        "tense": "past"
                    },
                    "text": "initiated",
                    "normalized": "initiate"
                }
            },
            {
                "subject": {
                    "text": "the virus"
                },
                "sentence": " -o2373, its vaccine candidate against -o-2, the virus that causes -19, with",
                "object": {
                    "text": "-19"
                },
                "action": {
                    "verb": {
                        "text": "cause",
                        "tense": "present"
                    },
                    "text": "causes",
                    "normalized": "cause"
                }
            },
            {
                "subject": {
                    "text": "quadrivalent influenza nanoparticle vaccine,"
                },
                "sentence": " quadrivalent influenza nanoparticle vaccine, met all primary objectives in its",
                "object": {
                    "text": "all primary objectives"
                },
                "action": {
                    "verb": {
                        "text": "meet",
                        "tense": "past"
                    },
                    "text": "met",
                    "normalized": "meet"
                }
            },
            {
                "subject": {
                    "text": "antibodies. ovavax"
                },
                "sentence": " antibodies. ovavax is a leading innovator of recombinant vaccines; its",
                "object": {
                    "text": "a leading innovator of recombinant vaccines"
                },
                "action": {
                    "verb": {
                        "text": "be",
                        "tense": "present"
                    },
                    "text": "is",
                    "normalized": "be"
                }
            },
            {
                "subject": {
                    "text": "proprietary recombinant technology platform"
                },
                "sentence": " proprietary recombinant technology platform combines the power and speed of",
                "object": {
                    "text": "the power"
                },
                "action": {
                    "verb": {
                        "text": "combine",
                        "tense": "present"
                    },
                    "text": "combines",
                    "normalized": "combine"
                }
            },
            {
                "subject": {
                    "text": "genetic engineering"
                },
                "sentence": " genetic engineering to efficiently produce highly immunogenic nanoparticles in",
                "object": {
                    "text": "highly immunogenic nanoparticles"
                },
                "action": {
                    "verb": {
                        "text": "produce",
                        "tense": "present"
                    },
                    "text": "produce",
                    "normalized": "produce"
                }
            },
            {
                "subject": {
                    "text": "statements regarding the manufacturing of"
                },
                "sentence": " and adjuvant products, including statements regarding the manufacturing of",
                "object": {
                    "text": "adjuvant products"
                },
                "action": {
                    "verb": {
                        "text": "include",
                        "tense": "present"
                    },
                    "text": "including",
                    "normalized": "include"
                }
            },
            {
                "subject": {
                    "text": "statements"
                },
                "sentence": " and adjuvant products, including statements regarding the manufacturing of",
                "object": {
                    "text": "the manufacturing of"
                },
                "action": {
                    "verb": {
                        "text": "regard",
                        "tense": "present"
                    },
                    "text": "regarding",
                    "normalized": "regard"
                }
            },
            {
                "subject": {
                    "text": "vaccine antigen dose amounts and timing,"
                },
                "sentence": " vaccine antigen dose amounts and timing, are forward-looking statements.",
                "object": {
                    "text": "forward-looking statements"
                },
                "action": {
                    "verb": {
                        "text": "be",
                        "tense": "present"
                    },
                    "text": "are",
                    "normalized": "be"
                }
            },
            {
                "subject": {
                    "text": "risks and uncertainties"
                },
                "sentence": " risks and uncertainties, which could cause actual results to differ materially",
                "object": {
                    "text": "actual results to differ materially"
                },
                "action": {
                    "verb": {
                        "text": "cause",
                        "tense": "future"
                    },
                    "text": "could cause",
                    "normalized": "could cause"
                }
            },
            {
                "subject": {
                    "text": "those identified under the heading \"isk actors\" in the"
                },
                "sentence": " uncertainties include those identified under the heading \"isk actors\" in the",
                "object": {
                    "text": "uncertainties"
                },
                "action": {
                    "verb": {
                        "text": "include",
                        "tense": "present"
                    },
                    "text": "include",
                    "normalized": "include"
                }
            },
            {
                "subject": {
                    "text": "by any uarterly eport"
                },
                "sentence": " with the ecurities and xchange ommission () and updated by any uarterly eport",
                "object": {
                    "text": "the ecurities and xchange"
                },
                "action": {
                    "verb": {
                        "text": "update",
                        "tense": "past"
                    },
                    "text": "updated",
                    "normalized": "update"
                }
            },
            {
                "subject": {
                    "text": "investors"
                },
                "sentence": " caution investors not to place considerable reliance on the forward-looking",
                "object": {
                    "text": "considerable reliance"
                },
                "action": {
                    "verb": {
                        "text": "place",
                        "tense": "future",
                        "negated": true
                    },
                    "text": "to place",
                    "normalized": "to place"
                }
            }
        ],
        "categories": [
            {
                "score": 0.948731,
                "label": "/health and fitness/disease"
            },
            {
                "score": 0.862764,
                "label": "/health and fitness/disease/cold and flu"
            },
            {
                "score": 0.823468,
                "label": "/health and fitness/disease/aids and hiv"
            }
        ],
        "relations": [
            {
                "type": "timeOf",
                "sentence": "(: ), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the company has been awarded a contract by the .. epartment of efense (o) for the manufacturing of -o2373, ovavax' -19 vaccine candidate.",
                "score": 0.975226,
                "arguments": [
                    {
                        "text": "today",
                        "location": [
                            358,
                            363
                        ],
                        "entities": [
                            {
                                "type": "Date",
                                "text": "today"
                            }
                        ]
                    },
                    {
                        "text": "announced",
                        "location": [
                            364,
                            373
                        ],
                        "entities": [
                            {
                                "type": "EventCommunication",
                                "text": "announced"
                            }
                        ]
                    }
                ]
            },
            {
                "type": "agentOf",
                "sentence": "(: ), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the company has been awarded a contract by the .. epartment of efense (o) for the manufacturing of -o2373, ovavax' -19 vaccine candidate.",
                "score": 0.567873,
                "arguments": [
                    {
                        "text": "company",
                        "location": [
                            383,
                            390
                        ],
                        "entities": [
                            {
                                "type": "Organization",
                                "text": "company",
                                "disambiguation": {
                                    "subtype": [
                                        "Commercial"
                                    ]
                                }
                            }
                        ]
                    },
                    {
                        "text": "awarded",
                        "location": [
                            400,
                            407
                        ],
                        "entities": [
                            {
                                "type": "EntertainmentAward",
                                "text": "awarded"
                            }
                        ]
                    }
                ]
            },
            {
                "type": "hasAttribute",
                "sentence": "-- through funding provided by the efense ealth rogram, has agreed to fund up to $60 million to support ovavax in its production of several components of the vaccine that will be manufactured in the .. he agreement includes a 2020 delivery of 10 million doses of -o2373 for o that could be used in hase 2/3 clinical trials or under an mergency se uthorization () if approved by the .. .",
                "score": 0.921106,
                "arguments": [
                    {
                        "text": "its",
                        "location": [
                            787,
                            790
                        ],
                        "entities": [
                            {
                                "type": "Organization",
                                "text": "biotechnology company"
                            }
                        ]
                    },
                    {
                        "text": "$60 million",
                        "location": [
                            754,
                            765
                        ],
                        "entities": [
                            {
                                "type": "Money",
                                "text": "$60 million",
                                "disambiguation": {
                                    "subtype": [
                                        "Gainloss"
                                    ]
                                }
                            }
                        ]
                    }
                ]
            },
            {
                "type": "employedBy",
                "sentence": "s an effective acquisition program, we put capable and supportable systems in the hands of the service members and first responders, when and where it is needed, at an affordable price.",
                "score": 0.885019,
                "arguments": [
                    {
                        "text": "members",
                        "location": [
                            2203,
                            2210
                        ],
                        "entities": [
                            {
                                "type": "Person",
                                "text": "members"
                            }
                        ]
                    },
                    {
                        "text": "service",
                        "location": [
                            2195,
                            2202
                        ],
                        "entities": [
                            {
                                "type": "Organization",
                                "text": "service",
                                "disambiguation": {
                                    "subtype": [
                                        "Military"
                                    ]
                                }
                            }
                        ]
                    }
                ]
            },
            {
                "type": "hasAttribute",
                "sentence": "he oalition for pidemic reparedness nnovations () is investing up to $388 million of funding to advance clinical development of -o2373.bout atrix-Movavax' patented saponin-based atrix-M adjuvant has demonstrated a potent and well- tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.bout ovavaxovavax, nc.",
                "score": 0.575297,
                "arguments": [
                    {
                        "text": "he",
                        "location": [
                            3348,
                            3350
                        ],
                        "entities": [
                            {
                                "type": "Person",
                                "text": "\u2011o2373"
                            }
                        ]
                    },
                    {
                        "text": "$388 million",
                        "location": [
                            3417,
                            3429
                        ],
                        "entities": [
                            {
                                "type": "Money",
                                "text": "$388 million",
                                "disambiguation": {
                                    "subtype": [
                                        "Gainloss"
                                    ]
                                }
                            }
                        ]
                    }
                ]
            }
        ],
        "keywords": [
            {
                "text": "adjuvant products",
                "relevance": 0.617696,
                "count": 1
            },
            {
                "text": "proprietary nanoparticle technology",
                "relevance": 0.617212,
                "count": 1
            },
            {
                "text": "ovavax' proprietary atrix",
                "relevance": 0.60303,
                "count": 1
            },
            {
                "text": "manufacture of the atrix",
                "relevance": 0.567973,
                "count": 1
            },
            {
                "text": "incorporate ovavax' proprietary saponin",
                "relevance": 0.564353,
                "count": 1
            },
            {
                "text": "prefusion protein antigen",
                "relevance": 0.559871,
                "count": 1
            },
            {
                "text": "epartment of efense ontract",
                "relevance": 0.559838,
                "count": 1
            },
            {
                "text": "clinical trials",
                "relevance": 0.553199,
                "count": 1
            },
            {
                "text": "hese risks",
                "relevance": 0.551809,
                "count": 1
            },
            {
                "text": "ovavax' recombinant nanoparticle technology",
                "relevance": 0.54693,
                "count": 1
            },
            {
                "text": "oint ervice's lead",
                "relevance": 0.546279,
                "count": 1
            },
            {
                "text": "late-stage biotechnology company",
                "relevance": 0.545269,
                "count": 1
            },
            {
                "text": "military personnel",
                "relevance": 0.544506,
                "count": 1
            },
            {
                "text": "biologics contract development",
                "relevance": 0.543528,
                "count": 1
            },
            {
                "text": "immune response",
                "relevance": 0.542625,
                "count": 2
            },
            {
                "text": "xecutive fficer of ovavax",
                "relevance": 0.541975,
                "count": 1
            },
            {
                "text": "2020ovavax",
                "relevance": 0.540919,
                "count": 1
            },
            {
                "text": "next-generation vaccines",
                "relevance": 0.540087,
                "count": 1
            },
            {
                "text": "components of the vaccine",
                "relevance": 0.532731,
                "count": 1
            },
            {
                "text": "high levels",
                "relevance": 0.531486,
                "count": 2
            },
            {
                "text": "coronavirus spike",
                "relevance": 0.530345,
                "count": 1
            },
            {
                "text": "genetic engineering",
                "relevance": 0.528955,
                "count": 1
            },
            {
                "text": "ovavax cautions",
                "relevance": 0.52723,
                "count": 1
            },
            {
                "text": "genetic sequence",
                "relevance": 0.526779,
                "count": 1
            },
            {
                "text": "production capacity",
                "relevance": 0.526393,
                "count": 1
            },
            {
                "text": "quadrivalent influenza nanoparticle vaccine",
                "relevance": 0.52621,
                "count": 1
            },
            {
                "text": "clinical development",
                "relevance": 0.526167,
                "count": 1
            },
            {
                "text": "nnual eport",
                "relevance": 0.525702,
                "count": 1
            },
            {
                "text": "clinical trial",
                "relevance": 0.525396,
                "count": 2
            },
            {
                "text": "s part",
                "relevance": 0.524486,
                "count": 1
            },
            {
                "text": "supportable systems",
                "relevance": 0.523267,
                "count": 1
            },
            {
                "text": "critical step",
                "relevance": 0.522437,
                "count": 1
            },
            {
                "text": "efense ealth rogram",
                "relevance": 0.520613,
                "count": 1
            },
            {
                "text": "injection site",
                "relevance": 0.520407,
                "count": 1
            },
            {
                "text": "critical aspect",
                "relevance": 0.518959,
                "count": 1
            },
            {
                "text": "uclear efense",
                "relevance": 0.518635,
                "count": 1
            },
            {
                "text": "future threats.bout",
                "relevance": 0.518161,
                "count": 1
            },
            {
                "text": "proprietary recombinant technology platform",
                "relevance": 0.516439,
                "count": 1
            },
            {
                "text": "antigen component",
                "relevance": 0.516305,
                "count": 1
            },
            {
                "text": "block binding of spike protein",
                "relevance": 0.516184,
                "count": 1
            },
            {
                "text": "effective acquisition program",
                "relevance": 0.515883,
                "count": 1
            },
            {
                "text": "pivotal hase",
                "relevance": 0.515371,
                "count": 1
            },
            {
                "text": "friendore announcementsriday",
                "relevance": 0.514398,
                "count": 1
            },
            {
                "text": "orm",
                "relevance": 0.512952,
                "count": 2
            },
            {
                "text": "affordable price",
                "relevance": 0.51294,
                "count": 1
            },
            {
                "text": "press release",
                "relevance": 0.512094,
                "count": 1
            },
            {
                "text": "older adults",
                "relevance": 0.511683,
                "count": 1
            },
            {
                "text": "primary objectives",
                "relevance": 0.511683,
                "count": 1
            },
            {
                "text": "contract",
                "relevance": 0.510285,
                "count": 2
            },
            {
                "text": "leading innovator of recombinant vaccines",
                "relevance": 0.510065,
                "count": 1
            }
        ]
    },
    "freqeuncy": "",
    "extracted_metadata": {
        "sha1": "285a50092f42075f68b12faff15fbd248b2369ed",
        "filename": "202006042334AMSPIDERAMC_USRE_INVES001_EBB61F073F751D6270D92E69021CDBFE_1.json",
        "file_type": "json"
    },
    "companyRecord": "",
    "publicationTime": "2020-06-04T23:34:00-04:00",
    "title": "Novavax, Inc. : Novavax Awarded Department of Defense Contract for COVID-19 Vaccine [Company Announcements for Eland Oil & Gas PLC]",
    "html": "<p>rintail a friendore announcementsriday 05 une, 2020ovavax, nc.ovavax warded epartment of efense ontract for -19 accine$60 million funding for manufacturing of -o237310 million doses to be delivered to o in 2020, d., une  04, 2020  ( ) -- ovavax, nc. (: ), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the company has been awarded a contract by the .. epartment of efense (o) for the manufacturing of &#8209;o2373, ovavax&#8217; -19 vaccine candidate. &#8209;o2373 consists of a stable, prefusion protein antigen made using its proprietary nanoparticle technology and includes ovavax&#8217; proprietary atrix&#8209;&#8482; adjuvant.-- through funding provided by the efense ealth rogram, has agreed to fund up to <money>$60 million</money> to support ovavax in its production of several components of the vaccine that will be manufactured in the .. he agreement includes a 2020 delivery of 10 million doses of &#8209;o2373 for o that could be used in hase 2/3 clinical trials or under an mergency se uthorization () if approved by the .. .&#8220;e are genuinely honored at the opportunity to protect our military personnel and their families who have devoted themselves to the needs of .. citizens and others worldwide,&#8221; said tanley . rck, resident and hief xecutive fficer of ovavax. &#8220;mportantly, this award will allow ovavax to significantly expand its .. production capacity of -o2373, a critical step in our ability to provide vaccine support to the -19 pandemic.&#8221;s part of the contract, ovavax will work with a ..-based biologics contract development manufacturing organization () to manufacture the antigen component of -o2373 for at least 10 million doses of vaccine. ovavax will also collaborate with ..-based s to scale up production and manufacture of the atrix- adjuvant component of the vaccine.bout the -he oint rogram xecutive ffice for hemical, iological, adiological and uclear efense is the oint ervice's lead for development, acquisition, fielding and life-cycle support of chemical, biological, radiological and nuclear defense equipment and medical countermeasures. s an effective acquisition program, we put capable and supportable systems in the hands of the service members and first responders, when and where it is needed, at an affordable price. ur vision is a resilient oint orce enabled to fight and win unencumbered by a chemical, biological, radiological, or nuclear environment; championed by innovative and state-of-the-art solutions.  nabling iotechnologies () is an organization established for the purpose of providing medical solutions, during a crisis, against future threats.bout -o2373&#8209;o2373 is a vaccine candidate engineered from the genetic sequence of &#8209;o&#8209;2, the virus that causes -19 disease. &#8209;o2373 was created using ovavax&#8217; recombinant nanoparticle technology to generate antigen derived from the coronavirus spike () protein and contains ovavax&#8217; patented saponin-based atrix-&#8482; adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. n preclinical trials, &#8209;o2373 demonstrated indication of antibodies that block binding of spike protein to receptors targeted by the virus, a critical aspect for effective vaccine protection.  hase 1 clinical trial of &#8209;o2373 initiated in ay 2020, with preliminary immunogenicity and safety results expected in uly 2020. he oalition for pidemic reparedness nnovations () is investing up to <money>$388 million</money> of funding to advance clinical development of &#8209;o2373.bout atrix-&#8482;ovavax&#8217; patented saponin-based atrix-&#8482; adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.bout ovavaxovavax, nc. (asdaq:) is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. ovavax recently initiated development of -o2373, its vaccine candidate against -o-2, the virus that causes -19, with hase 1 clinical trial results expected in uly of 2020. anolu&#8482;, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal hase 3 clinical trial in older adults. oth vaccine candidates incorporate ovavax&#8217; proprietary saponin-based atrix-&#8482; adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies. ovavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.or more information, visitwww.novavax.comwitterinkednorward-ooking tatementstatements herein relating to the future of ovavax and the ongoing development of its vaccine and adjuvant products, including statements regarding the manufacturing of vaccine antigen dose amounts and timing, are forward-looking statements. ovavax cautions that these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. hese risks and uncertainties include those identified under the heading &#8220;isk actors&#8221; in the ovavax nnual eport on orm 10- for the year ended ecember 31, 2019, as filed with the ecurities and xchange ommission () and updated by any uarterly eport on orm 10-, particularly the risks inherent to developing novel vaccines. e caution investors not to place considerable reliance on the forward-looking statements contained in this press release. ou are encouraged to read our filings with the , available atsec.govontacts:nvestors[email&#160;protected]estwickeedia</p>",
    "geoFocus": []
}